BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 04/26/19

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime, will present at the 26 th Annual American Society for Neural Therapy and Repair...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen ® , a retinal pigment epithelium (RPE) cell transplant t...

The following slide deck was published by BioTime, Inc. in conjunction with this Read more ...

BioTime (NYSEMKT: BTX ) closes its previously reported acquisition of Asterias Biotherapeutics, acquiring all of the remaining outstanding common stock of Asterias. More news on: BioTime, Inc., Healthcare stocks news, Read more ...

Company Will Advance Three Clinical Stage Product Candidates Addressing Significant Unmet Needs in Dry-AMD, Spinal Cord Injury, and Immuno-Oncology BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of Asterias Biotherapeu...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14 th , 2019, following the close of the U.S. f...

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette, PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc., will present the 14 th Annual Scientific Meeting of the ...

ALAMEDA, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen ® , a retinal pigment...

Immune Design (NASDAQ: IMDZ ) +312%  on being acquired by Merck. More news on: Immune Design, Sequans Communications, Community Health Systems, Inc., Stocks on the move, Read more ...

ALAMEDA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioT...